ArticleAnnals of oncology : official journal of the European Society for Medical Oncology2017
3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3).
Article in Annals of oncology : official journal of the European Society for Medical Oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Deep exploration of PARP inhibitors in breast cancer: monotherapy and combination therapy.The Journal of international medical research · 2021Pooled it
- Review of concepts in therapeutic decision-making in HER2-negative luminal metastatic breast cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2020Pooled it
- Second-Line Endocrine Therapy With or Without Palbociclib Rechallenge in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: PALMIRA Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Trial
- Everolimus plus exemestane in hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: incidence and time course of adverse events in the phase IIIb BALLET population.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2020Trial
- Trial
- Trial
- Integrative plasma-to-spatial proteomics reveals fibroblast-associated signatures in liver metastatic breast cancer.Cancer cell international · 2026Article
- Progression-free survival exceeding four years after transarterial embolization for liver metastases from triple-negative breast cancer: a case report.Frontiers in oncology · 2026Article
- PIV and PILE scores predict the clinical outcome in patients with metastatic breast cancer treated with CDK4/6 inhibitors.International journal of clinical oncology · 2025Article
- Real-world experience with CDK4/6 inhibitors in hormone receptor-positive metastatic and recurrent breast cancer: findings from an Asian population.Clinical and experimental medicine · 2024Article
- Clinicopathological analysis of 38 male patients diagnosed with breast cancer.Breast disease · 2024Article
- Plasma apolipoprotein M predicts overall survival in metastatic breast cancer patients.Breast cancer research and treatment · 2023Article
- Analysis of the metastatic mechanism and progress in the treatment of breast cancer liver metastasis: a narrative review.Translational cancer research · 2023Review
- A phase Ib study of TQB2450 plus anlotinib in patients with advanced triple-negative breast cancer.iScience · 2023Article
- The genomic landscape associated with resistance to aromatase inhibitors in breast cancer.Genomics & informatics · 2023Article
- CDK4/6 inhibitor resistance mechanisms and treatment strategies (Review).International journal of molecular medicine · 2022Review
- Article
- Exploring the influencing factors of the pathologic complete response in estrogen receptor-positive, HER2-negative breast cancer after neoadjuvant chemotherapy: a retrospective study.World journal of surgical oncology · 2022Article
- LncRNA SNHG5 promotes the glycolysis and proliferation of breast cancer cell through regulating BACH1 via targeting miR-299.Breast cancer (Tokyo, Japan) · 2022Article
- Diagnosis, biology and epidemiology of oligometastatic breast cancer.Breast (Edinburgh, Scotland) · 2021Review
Corrections and comments
- Erratum for
Authors and funding
45 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.